Atossa Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Atossa Therapeutics has a total shareholder equity of $80.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $85.9M and $5.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$79.53m |
| Equity | US$80.16m |
| Total liabilities | US$5.70m |
| Total assets | US$85.86m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YAG2's short term assets ($81.7M) exceed its short term liabilities ($5.7M).
Long Term Liabilities: YAG2 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: YAG2 is debt free.
Reducing Debt: YAG2 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YAG2 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if YAG2 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.